Vascular benefit of the use of mepivacaine as an anaesthetic in resilient hyaluronic acid® injectables
Lidocaine (0.3% w/w) has long been used in HA-based injectables for pain relief, but mepivacaine may be a better alternative, offering similar efficacy without vasodilation, potentially lowering the risk of adverse events.
Authors
- Lee Walker
- Lukas Roubenne (ORCID: https://orcid.org/0000-0003-1039-857X)
- François Bourdon
- Romain Brusini
- Jimmy Faivre (ORCID: https://orcid.org/0000-0003-4695-1816)
- Jing Jing (ORCID: https://orcid.org/0000-0002-5841-4826)
- Conor J. Gallagher
- Bruno Le Grand
- Sabrina Walley
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Liverpool City Council (GB)
Publication Details
- Journal
- RSC Pharmaceutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1039/d5pm00069f
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00